Role of capsule and O antigen in the virulence of uropathogenic Escherichia coli

PLoS One. 2014 Apr 10;9(4):e94786. doi: 10.1371/journal.pone.0094786. eCollection 2014.

Abstract

Urinary tract infection (UTI) is one of the most common bacterial infections in humans, with uropathogenic Escherichia coli (UPEC) the leading causative organism. UPEC has a number of virulence factors that enable it to overcome host defenses within the urinary tract and establish infection. The O antigen and the capsular polysaccharide are two such factors that provide a survival advantage to UPEC. Here we describe the application of the rpsL counter selection system to construct capsule (kpsD) and O antigen (waaL) mutants and complemented derivatives of three reference UPEC strains: CFT073 (O6:K2:H1), RS218 (O18:K1:H7) and 1177 (O1:K1:H7). We observed that while the O1, O6 and O18 antigens were required for survival in human serum, the role of the capsule was less clear and linked to O antigen type. In contrast, both the K1 and K2 capsular antigens provided a survival advantage to UPEC in whole blood. In the mouse urinary tract, mutation of the O6 antigen significantly attenuated CFT073 bladder colonization. Overall, this study contrasts the role of capsule and O antigen in three common UPEC serotypes using defined mutant and complemented strains. The combined mutagenesis-complementation strategy can be applied to study other virulence factors with complex functions both in vitro and in vivo.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigens, Bacterial / metabolism*
  • Bacterial Capsules / metabolism*
  • Escherichia coli Infections / immunology
  • Escherichia coli Infections / microbiology*
  • Escherichia coli Proteins
  • Mice
  • O Antigens / genetics
  • O Antigens / metabolism*
  • Ribosomal Protein S9
  • Urinary Tract Infections / immunology
  • Urinary Tract Infections / microbiology*
  • Uropathogenic Escherichia coli / immunology
  • Uropathogenic Escherichia coli / pathogenicity*
  • Virulence

Substances

  • Antigens, Bacterial
  • Escherichia coli Proteins
  • O Antigens
  • Ribosomal Protein S9
  • RpsI protein, E coli

Grants and funding

This work was supported by grants from the Australian National Health and Medical Research Council (APP1012076 and APP1005315). GCU and MAS are supported by Australian Research Council Future Fellowships (FT110101048 and FT100100662, respectively). MT is supported by an Australian Research Council Discovery Early Career Researcher Award (DE130101169). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.